Effects of bromocriptine in Huntington chorea. Case report.
1. The effects of bromocriptine (BC) on choreiform movement were compared with those of bromperidol (BP) and fluphenazine (FLZ) in a patient with Huntington disease. The patient (male, 42 years old) was treated with BP (15 mg/day, 4 weeks), FLZ (3 mg/day, 4 weeks), low dose of BC (5 mg/day, 4 weeks) and relatively high dose of BC (10 mg/day, 8 weeks). The CSF content of homovanilic acid (HVA) was assayed at last day of the each drug trial. The efficacy of the drugs was evaluated by electromyography. 2. Although BP and FLZ did not succeed to ameliorate the choreiform movement, both low dose and high dose BC showed rapid improvement of the involuntary movement. The CSF HVA concentration was 35.0 ng/ml before beginning treatment. Whereas FLZ and high dose of BC substantially increased the levels of HVA after the dosage (49.3 and 53.1 ng/ml, respectively), moderate increase of HVA (41.5 ng/ml) was observed when the low dose of BC was administered. These observations suggest that increase of CSF HVA might be necessary for clinical improvement of choreiform movement but not correlate with the degree of improvement and dopamine agonists could be useful drug for the treatment of choreiform movement which is refractory to the administration of neuroleptics.
Tsuneizumi
T
T
Department of Neuropsychiatry, St. Marianna University, Yokohama City Seibu Hospital, Kanagawa, Japan.
Anai
K
K
Aoba
A
A
Yamaguchi
N
N
Takagi
H
H
Chishima
T
T
Sakai
T
T
Negishi
K
K
Kamimura
M
M
Takeshita
T
T
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D004576:Electromyography / Q000187:drug effects; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D008297:Male; D010375:Pedigree
D001971:Bromocriptine